Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | PTGES | O14684 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5963966 | 0.88 | MEN1 (0.47) | MEN1KMT2APTGESMAPK1LMNA | |
| SCHEMBL6192984 | 0.87 | CNR2 (0.55) | CNR2MEN1KMT2AMAPK1LMNA | |
| SCHEMBL5964019 | 0.87 | CNR2 (0.55) | CNR2MEN1KMT2AMAPK1LMNA | |
| SCHEMBL5964313 | 0.83 | CNR2 (0.51) | CNR2MEN1KMT2A | |
| SCHEMBL6190788 | 0.83 | CNR2 (0.51) | CNR2MEN1KMT2A | |
| SCHEMBL5964301 | 0.82 | CNR2 (0.58) | CNR2MEN1KMT2AMAPK1LMNA | |
| SCHEMBL5964288 | 0.82 | CNR2 (0.67) | CNR2MEN1KMT2AMAPK1LMNA | |
| SCHEMBL5964327 | 0.82 | CNR2 (0.57) | CNR2MEN1KMT2AMAPK1PRMT5 | |
| SCHEMBL5964260 | 0.80 | CNR2 (0.60) | CNR2MEN1KMT2AMAPK1LMNA | |
| SCHEMBL5964150 | 0.80 | CNR2 (0.60) | CNR2MEN1KMT2AMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052315-A1 | Cb 1/cb 2 receptor ligands and their use in the treatment of pain | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052315-A1 | Cb 1/cb 2 receptor ligands and their use in the treatment of pain | CNR1, CNR2, OPRL1 | CNR2 2/4885MEN1 4443/4885KMT2A 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.